Cynosure Receives Approval in Korea and Taiwan to Market PicoSure™, the First Picosecond Laser to Remove Tattoos and Benign Pigmented Lesions

Cynosure

, a leader in laser- and light-based aesthetic treatments for non-invasive and minimally invasive applications, today announced that its PicoSure™ Picosecond Laser has received marketing authorization in Korea from the country's Ministry of Food and Drug Safety and in Taiwan from the Taiwan Food and Drug Administration (TFDA). The product will be marketed through the Company's direct sales force in Korea and through its third-party distributor in Taiwan. "PicoSure is building a loyal worldwide following among physicians and their patients seeking a safe, effective treatment for the removal of tattoos and benign pigmented lesions," said Cynosure President and Chief Executive Officer Michael Davin. "We continue to make excellent progress in broadening the product's reach to key international markets and consumers." In addition to PicoSure, the TFDA granted marketing authorization to two other Cynosure products: Smartlipo Triplex™ LaserBodySculpting™ Workstation, the industry's leading laser-assisted lipolysis system designed to disrupt fat cells and tighten tissue through tissue coagulation; and Apogee+, a 755 nm Alexandrite laser for removal of hair and epidural lesions on a wide range of skin types. "Our recent approvals in Korea and Taiwan underscore the significant role that the Asia-Pacific market plays in our international growth strategy," Davin said. "We look forward to continuing to expand our brand leadership in the region." About Cynosure, Inc. Cynosure develops and markets aesthetic treatment systems that enable plastic surgeons, dermatologists and other medical practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and benign pigmented lesions, remove multi-colored tattoos, revitalize the skin, liquefy and remove unwanted fat through laser lipolysis, reduce cellulite, clear nails infected by toe fungus and ablate sweat glands. Cynosure's product portfolio is composed of a broad range of energy sources including Alexandrite, diode, Nd: YAG, picosecond, pulse dye, and Q-switched lasers and intense pulsed light. Cynosure sells its products globally under the Cynosure, Palomar and ConBio brand names through a direct sales force in the United States, Canada, Mexico, France, Germany, Spain, the United Kingdom, Australia, China, Japan and Korea, and through international distributors in approximately 100 other countries. For corporate or product information, visit Cynosure's website at www.cynosure.com. Forward-Looking Statements Any statements in this press release about future expectations, plans and prospects for Cynosure, Inc., as well as other statements containing the words "believes," "anticipates," "plans," "expects," "will" and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including market acceptance of PicoSure in Korea, market acceptance of PicoSure, Smartlipo Triplex and Apogee+ in Taiwan, levels of demand for procedures performed with Cynosure products and for Cynosure products themselves, competition in the aesthetic laser industry, general business and economic conditions and other factors discussed in Cynosure's most recent Annual Report on Form 10-K and subsequently filed quarterly reports on Form 10-Q, which are filed with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent Cynosure's views as of the date of this press release. Cynosure anticipates that subsequent events and developments will cause its views to change. However, although Cynosure may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Cynosure's views as of any date subsequent to the date of this press release.